United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.54% | 7.56% | 9.43% | -3.94% | 6.94% |
| Total Depreciation and Amortization | -0.88% | 4.11% | 3.79% | 6.57% | 0.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.79% | 164.36% | -39.16% | 55.58% | 203.78% |
| Change in Net Operating Assets | 108.61% | -188.62% | 180.05% | -360.26% | 30.22% |
| Cash from Operations | 33.82% | -38.41% | 193.22% | -58.43% | 35.17% |
| Capital Expenditure | 41.70% | 17.86% | -238.42% | 16.96% | 13.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,643.88% | -115.57% | 247.83% | -164.70% | -146.03% |
| Cash from Investing | 426.76% | -261.53% | 146.98% | -82.09% | -33.69% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -300.00% | 0.00% |
| Issuance of Common Stock | -25.35% | 122.47% | 145.86% | -15.81% | -16.02% |
| Repurchase of Common Stock | -259,616.67% | 99.94% | -19,140.38% | 66.01% | -5,000.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -1,608.54% | 110.29% | -381.37% | -111.73% | -25.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -227.83% | 185.77% | 17.54% | -251.36% | 41.45% |